https://www.researchgate.net/publication/345720814_First_clinical_results_for_PSMA_targeted_alpha_therapy_using_225Ac-PSMA-IT_in_advanced_mCRPC_patients
typically companies get bought on lead indications. This is fusion's lead assets P1 results. Cu6 has yet to complete their P1, as their final cohort is pending. Hard to determine which therapy is better just yet, but looking at the results, I feel cu6 has the better asset, but I am aware of my bias.
fusion is probably 12-18 months ahead of cu6, which may be a factor in why no one has looked to acquire cu6 yet. Our data, while very promising, is still early(P1).
Clarity VS Fusion, page-3
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$4.07 |
Change
-0.020(0.49%) |
Mkt cap ! $1.265B | |||
| Open | High | Low | Value | Volume |
| $4.10 | $4.13 | $3.96 | $3.181M | 791.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 6181 | $4.05 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.12 | 4000 | 1 |
View Market Depth
| Last trade - 16.10pm 22/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$4.10 |
Change
-0.020 ( 0.11 %) |
||||
| Open | High | Low | Volume | ||
| $4.12 | $4.12 | $3.96 | 45540 | ||
| Last updated 15.59pm 22/05/2024 ? | |||||
| CU6 (ASX) Chart |